ARCA Biopharma, Inc. (NASDAQ: ABIO) 89.3% HIGHER; today announced that the U.S. FDA has designated as a Fast Track development program the investigation of Gencaro, the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator, for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population.
beta blockerUnusual 11 Mid-Day Movers 11/23: ABIO, SEED, FNET, CDTI Higher; ...StreetInsider.com News Articles Mon, 11/23/2009 - 11:55
Morning Movers 11/23: ABIO, SEED, FIF, FNET, DDRX, JOBS Higher; ...StreetInsider.com News Articles Mon, 11/23/2009 - 09:03
ARCA Biopharma, Inc. (NASDAQ: ABIO) 47.6% HIGHER; today announced that the U.S. FDA has designated as a Fast Track development program the investigation of Gencaro, the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator, for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population. |
